|drug46||21% Ethanol plus essential oils Wiki||1.00|
|drug2293||Matched Placebo Hydroxychloroquine Wiki||1.00|
|drug6||0.12% Chlorhexidine Gluconate Wiki||1.00|
|D003141||Communicable Diseases NIH||0.07|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
The number of confirmed cases of COVID-19 infectious disease arising from the SARS-CoV-2 coronavirus is rising substantially and rapidly, with the potential to overwhelm the ability of the entire National Health Service (NHS) to cope with the increased demand. The availability of personal protective equipment is limited and reports of high risk procedures such as aerosol generating procedures (e.g. intubation for the sickest patients) is a source of great concern for infection transmission. Frontline NHS staff with direct patient contact have the highest likelihood of exposure to SARS-CoV-2 and development of COVID-19 disease. Efforts to protect these workers from development of COVID-19, using drugs to prevent the disease, require urgent evaluation.
Description: Time taken for incidence of COVID-19 disease between Hydroxychloroquine and placebo armsMeasure: Time to positive COVID-19 disease Time: Assessed up to 90 days
Description: Number of COVID-19 symptoms based on clinical guidelines and test positive infections per study armMeasure: Number of COVID-19 test positive cases Time: Assessed up to 90 days
Description: Number of test positive COVID-19 serological test positive cases per study armMeasure: Number of COVID-19 serological test positive cases Time: Assessed up to 90 days
Description: Severity based on hospitalisationMeasure: Severity of COVID-19 disease between each arm Time: Assessed up to 90 days
Description: Number of common COVID-19 complications between armsMeasure: Number of common COVID-19 complications between each arm Time: Assessed up to 90 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports